SRS LAB

  Our laboratory is dedicated to deconstructing the life cycles of RNA viruses, with a primary focus on Enterovirus, Influenza, and Coronaviruses. We investigate how viral non-translated regions (UTRs) regulate translation and explore the mechanisms by which viral proteins disrupt host cellular processes, such as apoptosis regulation. By unraveling these fundamental molecular interactions, we identify the core drivers of viral pathogenesis, providing critical scientific evidence for the clinical prediction of severe disease.  

  In response to the continuous evolution of emerging viruses, our laboratory integrates genomic surveillance, molecular evolution, and statistical analysis to track viral mutation trends and geographic transmission pathways. Our work encompasses cross-species transmission of influenza and the monitoring of SARS-CoV-2 variants. These big data-driven insights provide critical early-warning information for public health policies and are essential for evaluating the efficacy of current diagnostics and clinical treatments.

  Utilizing clinical samples from natural infections and vaccinations, our team evaluates the persistence and cross-protective efficacy of host neutralizing antibodies. We place a particular emphasis on immune system dynamics within specific populations, such as medical staffs and hemodialysis patients, while exploring immune cross-reactivity between different viruses. Our findings provide critical scientific foundations for the precision design of next-generation vaccines and the optimization of clinical immunization strategies.

  Our team is committed to advancing translational research for emerging infectious diseases. Leveraging our insights into viral vulnerabilities, we focus on two core areas: on the therapeutic front, we develop potent broad-spectrum antiviral peptides, novel antibody-based drugs, and natural extracts; on the diagnostic front, we integrate interdisciplinary engineering to build high-sensitivity biosensing platforms. Through this dual-track R&D approach, we aim to achieve precision screening and early therapeutic intervention against emerging viral threats.